Botulinum toxin A - Allergan

Drug Profile

Botulinum toxin A - Allergan

Alternative Names: AGN 191622; Botox; GSK 1358820; Oculinum; Onabotulinum toxin A; Vistabel; Vistabex

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Allergan
  • Developer Allergan; GlaxoSmithKline; Johns Hopkins University; Wake Forest University School of Medicine
  • Class Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Muscle relaxants
  • Mechanism of Action Acetylcholine inhibitors; Glutamate receptor antagonists; Glutamate-antagonists; Neuromuscular blocking agents; Substance P release inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Muscle spasticity; Torticollis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Blepharospasm; Facial-wrinkles; Glabellar lines; Hyperhidrosis; Migraine; Muscle spasticity; Neurogenic bladder; Overactive bladder; Strabismus; Torticollis
  • Registered Equinus foot deformity
  • Phase III Raynaud's disease
  • Phase II Herpes labialis; Hypertrophy; Major depressive disorder; Musculoskeletal pain; Pain; Premature ejaculation
  • No development reported Benign prostatic hyperplasia
  • Discontinued Diabetic gastroparesis; Gilles de la Tourette's syndrome

Most Recent Events

  • 13 Feb 2017 The Scottish Medicines Consortium advices restricted use of botulinum toxin A within NHS Scotland
  • 01 Dec 2016 Allergan completes a phase II trial in Major depressive disorder in USA (NCT02116361)
  • 01 Oct 2016 Phase-III clinical trials in Neurogenic bladder in Japan (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top